Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2017 Future Medicine Ltd. Dr Mead earned his medical degree from the University of Oxford and trained in hematology at St Bartholomew's Hospital and University College London. In 2007, he earned his PhD at UCL, which focused on the analysis of FLT3 mutations in acute myeloid leukemia. He is now Associate Professor of Hematology and MRC Senior Clinical Fellow at the WIMM, University of Oxford. His research group focuses on myeloid diseases and normal blood stem-cell biology. Dr Mead is the lead clinician for myeloproliferative neoplasms (MPN) and chronic myeloid leukemia in the Thames Valley Strategic Clinical Network and is the chief investigator for several chronic myeloid leukemia and MPN clinical trials. Additionally, Dr Mead has helped shape the diagnostic and treatment guidelines for MPNs in the UK and serves as the chair of the MPN clinical study subgroup of the National Cancer Research Institute.

Original publication

DOI

10.2217/fon-2017-0460

Type

Journal article

Journal

Future Oncology

Publication Date

01/11/2017

Volume

13

Pages

2401 - 2404